Qdenga Dengue Vaccine and Public Health Strategy for UPSC Prelims – Prelims Specific

Introduction

Dengue remains a significant public health threat in India, exacerbated by urbanization and climate change. The global development of the Qdenga vaccine has sparked debate over its integration into India's national health strategy, requiring a balance between clinical innovation and the practical realities of India's diverse epidemiological landscape.

Why in News?

• Global health regulators have granted approvals for the Qdenga vaccine.
• Indian health authorities are currently evaluating the feasibility of adopting the vaccine as a tool for public health management, shifting focus from pure vector-control towards biomedical interventions.

Static Link

• Subject: Science and Technology (Biotechnology/Health).
• Concept: Dengue is a viral disease caused by the DENV virus, which has four distinct serotypes (DENV-1, DENV-2, DENV-3, and DENV-4).
• Vaccine Mechanism: Qdenga is a live-attenuated tetravalent vaccine, meaning it contains weakened versions of all four virus types to induce broad-spectrum immunity.
• Prelims Linkage: UPSC often focuses on vaccine types (live-attenuated vs. inactivated vs. mRNA) and the biological mechanisms of viral transmission.

Institutional Link

• Central Drugs Standard Control Organisation (CDSCO): The national regulatory body responsible for approval of drugs and vaccines in India.
• Indian Council of Medical Research (ICMR): Apex body for biomedical research, involved in conducting seroprevalence studies.
• National Vector Borne Disease Control Programme (NVBDCP): Operates under the National Health Mission (NHM) to manage diseases like dengue through integrated vector control.
• World Health Organization (WHO): Sets global guidelines and standards for immunization and disease control.

Core Prelims Facts

• Qdenga is a live-attenuated, tetravalent vaccine developed by Takeda Pharmaceutical.
• Dengue is transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes.
• The vaccine is designed to mitigate the risk of severe disease and hospitalization.
• Vaccination success depends on local serotype prevalence and the patient's history of dengue infection.

Important Terms and Concepts

• Antibody-dependent enhancement (ADE): A phenomenon where antibodies from a previous infection/vaccination facilitate the entry of a different dengue serotype into cells, potentially leading to severe disease.
• Tetravalent: A vaccine that provides protection against four different strains or serotypes of a pathogen.
• Live-attenuated vaccine: A vaccine using a weakened form of the germ that causes a disease.

Bodies / Organisations / Institutions

• CDSCO: Statutory body under the Ministry of Health and Family Welfare (MoHFW) for drug regulation.
• NVBDCP: Executive programme for managing vector-borne diseases.

Schemes / Laws / Reports / Conventions

• National Health Mission (NHM): The overarching framework for public health initiatives in India.
• Integrated Vector Management (IVM): The global strategy promoted by WHO for controlling vector-borne diseases.

Possible UPSC Prelims Traps

• Vaccine Nature: Traps may label Qdenga as an inactivated vaccine, which is incorrect.
• Serotype Coverage: Questions may suggest it targets only one serotype; it is tetravalent (targets all four).
• Regulatory Authority: Confusing the roles of ICMR (research-focused) with CDSCO (regulatory/approval-focused).
• Disease Transmission: Assuming dengue is transmitted by the Anopheles mosquito (it is Aedes).
• Absolute Claims: Statements suggesting the vaccine is a universal replacement for vector control are likely to be incorrect in a UPSC context.

One-Minute Revision Notes

• Qdenga: Live-attenuated, tetravalent, targets four DENV serotypes.
• Vector: Transmitted by Aedes aegypti.
• Regulatory: CDSCO is the primary Indian authority for vaccine approvals.
• Challenge: Antibody-dependent enhancement remains a key hurdle in vaccine efficacy.
• Strategy: Integrated Vector Management is the current backbone of Indian policy under NVBDCP.

Practice MCQ for Prelims

Q. Consider the following statements regarding the Dengue vaccine (Qdenga)

1. It is an inactivated vaccine that uses killed dengue virus particles.

2. It is designed to provide protection against all four serotypes of the dengue virus.

Which of the statements given above is/are correct?

A) 1 only

B) 2 only

C) Both 1 and 2

D) Neither 1 nor 2

Answer: B

Explanation: Qdenga is a live-attenuated vaccine, not an inactivated one. It is indeed tetravalent, meaning it targets all four serotypes (DENV-1 to 4).